The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Differential impact of mammalian target of rapamycin inhibition on CD4 +CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells
Open accessAbstract
Based on their ability to control T-cell homeostasis, Foxp3+CD4+CD25+ regulatory T cells (Tregs) are being considered for treatment of autoimmune disorders and acute graft-versus-host disease (aGVHD). When combining Tregs with the immunosuppressant rapamycin (RAPA), we observed reduced alloreactive conventional T-cell (Tconv) expansion and aGVHD lethality compared with each treatment alone. This synergistic in vivo protection was paralleled by intact expansion of polyclonal Tregs with conserved high FoxP3 expression. In contrast to Tconv, activation of Tregs with alloantigen and interleukin-2 preferentially led to signal transducer and activator of transcription 5 (STAT5) phosphorylation and not phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway activity. Expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a negative regulator of the PI3K/Akt/mTOR pathway, remained high in Tregs but not Tconv during stimulation. Conversely, targeted deletion of PTEN increased susceptibility of Tregs to mTOR inhibition by RAPA. Differential impact of RAPA as a result of reduced usage of the mTOR pathway in Tregs compared with conventional T cells explains the synergistic effect of RAPA and Tregs in aGVHD protection, which has important implications for clinical trials using Tregs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beneficial downstream effects include Treg generation, suppressing CTL and T helper (TH) activation and at higher doses, B-cell proliferation and differentiation (69–71).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,315
Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data
Sachs, K., Perez, O. D., Pe’er, D., Lauffenburger, D. A., & Nolan, G. P. (2005) · Science · doi:10.1126/science.1105809 · Cited by 1,785
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729
CD4+CD25+ Immunoregulatory T Cells
McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395
Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C. G., Strober, S., & Negrin, R. S. (2003) · Nature Medicine · doi:10.1038/nm915 · Cited by 1,286
Self-citationFOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT
Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A. D., Stroud, J. C., Bates, D. L., Guo, L., Han, A., Ziegler, S. F., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.042 · Cited by 1,229
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.
Battaglia, M., Stabilini, A., & Roncarolo, M. (2005) · Blood · doi:10.1182/blood-2004-10-3932 · Cited by 1,203
Burchill, M. A., Yang, J., Vogtenhuber, C., Blazar, B. R., & Farrar, M. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.280 · Cited by 831
Battaglia, M., Stabilini, A., Migliavacca, B., Horejs‐Hoeck, J., Kaupper, T., & Roncarolo, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8338 · Cited by 746
Kingsley, C. I., Karim, M., Bushell, A., & Wood, K. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1080 · Cited by 742
Cited by
Sorted by citations
Park, J., Kim, M., Kang, S. G., Jannasch, A. H., Cooper, B., Patterson, J., & Kim, C. H. (2015) · Mucosal Immunology · doi:10.1038/mi.2014.44 · Cited by 1,307
Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1609337 · Cited by 1,347
Self-citationBrunstein, C. G., Miller, J. S., Cao, Q., McKenna, D. H., Hippen, K. L., Curtsinger, J., DeFor, T. E., Levine, B. L., June, C. H., Rubinstein, P., et al. (2010) · Blood · doi:10.1182/blood-2010-07-293795 · Cited by 1,052
Regulation and function of mTOR signalling in T cell fate decisions
Chi, H. (2012) · Nature Reviews Immunology · doi:10.1038/nri3198 · Cited by 1,035
Signaling and Function of Interleukin-2 in T Lymphocytes
Ross, S. H., & Cantrell, D. A. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053352 · Cited by 1,025
Metadata
- Authors
- Zeiser, R., Leveson-Gower, D. B., Zambricki, E. A., Kambham, N., Beilhack, A., Loh, J., Hou, J.-Z., & Negrin, R. S.
- Affiliations
- University of Freiburg (DE)
- Stanford Medicine (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-01-01
- Volume
- 111
- Issue
- 1
- Pages
- 453-462
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC2200823
- OpenAlex
- W1981298448
- Cited by
- 402
- References
- 52
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 9 · 2023: 17 · 2022: 9 · 2021: 21 · 2020: 17 · 2019: 21 · 2018: 23 · 2017: 18 · 2016: 31 · 2015: 24 · 2014: 33 · 2013: 27 · 2012: 32
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Krebshilfe
- National Institutes of Health (HL075462)
- National Heart, Lung, and Blood Institute (P01HL075462)
- National Cancer Institute (P50CA114747, R01 CA0800065, HL075462, R24 CA 92862, R24CA092862)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- regulatory T cells, mTOR inhibition, rapamycin, acute graft-versus-host disease, conventional CD4+ T cells, STAT5 phosphorylation, PI3K/AKT/mTOR pathway, PTEN, Foxp3, interleukin-2, Treg therapy
- MeSH terms
- Animals, Graft vs Host Disease, Immunosuppressive Agents, Mice, Inbred BALB C, Mice, Inbred C57BL, Protein Kinases, CD4-Positive T-Lymphocytes, Hematopoietic Stem Cell Transplantation, Phosphatidylinositol 3-Kinases, Sirolimus, T-Lymphocytes, Regulatory, STAT5 Transcription Factor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Forkhead Transcription Factors, Interleukin-2 Receptor alpha Subunit, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
